Salsalate is poorly tolerated and fails to improve endothelial function in virologically suppressed HIV-infected adults.
In this 13-week, open-label, randomized study of the anti-inflammatory salsalate versus usual care, there were no significant improvements in flow-mediated dilation of the brachial artery, endothelial activation, inflammation or coagulation markers, homeostasis model assessment of insulin resistance or lipoproteins with salsalate or between groups in virologically suppressed, HIV-infected adults on antiretrovirals. Tinnitus and transaminitis occurred frequently in the salsalate group. Dose reduction due to toxicities encountered and low level of inflammation may explain these results.
Hileman
Corrilynn O
CO
University Hospitals Case Medical Center and Case Western Reserve University, Cleveland, Ohio 44106, USA.
Carman
Teresa L
TL
Gripshover
Barbara M
BM
O'Riordan
Maryann
M
Storer
Norma J
NJ
Harrill
Danielle E
DE
White
Cynthia A
CA
McComsey
Grace A
GA
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000009:adverse effects; D001916:Brachial Artery / Q000503:physiopathology*; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D007333:Insulin Resistance; D008297:Male; D012459:Salicylates / Q000008:administration & dosage* / Q000009:adverse effects
D000894:Anti-Inflammatory Agents, Non-Steroidal; D012459:Salicylates; C014182:salicylsalicylic acid